Replies to post #79284 on Biotech Values

[mcbio]

Re: PSI-7851 vs. IDX184

PSI-7851 has demonstrated potent in vitro anti-HCV activity with EC50 values of 90 +/- 60 nM, which is approximately 15- to 20-fold more potent than Pharmasset's first generation nucleoside polymerase inhibitor, R7128

I believe IDX-184 has a lower (better) EC50 compared to R7128. however both are plenty potent, so this disparity is unlikely to be clinically meaningful unless the lower dose of the idenix compound translates into a better SE profile

Do you mean that IDX184 has a lower (better) EC50 compared to PSI-7851? I expect IDX184 to be more potent than R7128 since IDX184 is more of a second generation compound whereas R7128 is a first generation compound. Also, see my reply to Dew about VRUS' use of "generally" in their PR today with respect to the safety and tolerability of PSI-7851 as I am curious if there is something we should take away from that disclosure.